Start Rivaroxaban (or Another NOAC)
For this 54-year-old man with subsegmental PE, stage 3A CKD (eGFR 58), and no hemodynamic instability, you should initiate oral anticoagulation with rivaroxaban or another NOAC rather than warfarin or IV heparin. 1
Risk Stratification
This patient has low-risk PE based on:
- Normal vital signs except mild tachycardia (HR 110)
- No right heart strain on CT
- Subsegmental location only
- Oxygen saturation 91% (mild hypoxemia but not critically low)
- Hemodynamically stable (BP 135/75)
The ESC guidelines clearly stratify PE management by risk, and this patient does not meet criteria for high-risk or intermediate-risk PE requiring IV heparin or consideration of thrombolysis 1.
Anticoagulation Choice: NOACs Over Warfarin and IV Heparin
The 2019 ESC guidelines give a Class I, Level A recommendation that NOACs (apixaban, dabigatran, edoxaban, or rivaroxaban) are preferred over VKAs (warfarin) when initiating oral anticoagulation in eligible PE patients. 1
For low-risk PE specifically:
- LMWH or fondaparinux is preferred over UFH for parenteral initiation (Class I, Level A) 1
- However, NOACs can be started directly without parenteral bridging (rivaroxaban and apixaban have this advantage)
- IV heparin infusion is reserved for high-risk PE requiring immediate full anticoagulation before thrombolysis 1
Addressing the CKD Concern
His eGFR of 58 mL/min (stage 3A CKD) does not contraindicate NOACs. The ESC guidelines state NOACs are contraindicated only in severe renal impairment 1. Severe renal impairment typically means:
- CrCl <30 mL/min for rivaroxaban and apixaban
- CrCl <15 mL/min for apixaban specifically
With an eGFR of 58, this patient is well above these thresholds and can safely receive any NOAC with appropriate dosing.
Subsegmental PE Considerations
The 2021 CHEST guidelines address isolated subsegmental PE (ISSPE) specifically 2. While they suggest surveillance without anticoagulation may be considered in highly selected cases, this patient has multiple features favoring anticoagulation:
Features supporting true-positive PE and need for anticoagulation:
- Symptomatic presentation (chest pain, cough, hypoxemia to 91%)
- Tachycardia (HR 110)
- Multiple cardiovascular risk factors (HTN, DM, obesity, CKD)
- No identified reversible risk factor
- Reduced mobility likely (cab driver, obesity BMI 35)
The CHEST guidelines note that symptomatic patients, those with elevated clinical probability, and those with reduced cardiopulmonary reserve should receive anticoagulation even for subsegmental PE 2.
Why Not the Other Options?
- Warfarin: Inferior to NOACs per Class I recommendation; requires parenteral bridging, INR monitoring, dietary restrictions, and drug interactions 1
- Enoxaparin alone: Would be appropriate for parenteral initiation but should transition to oral anticoagulation; NOACs can be started directly
- IV heparin infusion with admission: Reserved for high-risk PE with hemodynamic instability; this patient is stable and could potentially be considered for early discharge 1
Practical Implementation
Rivaroxaban dosing for PE:
- 15 mg PO twice daily for 21 days
- Then 20 mg PO once daily
Apixaban alternative:
- 10 mg PO twice daily for 7 days
- Then 5 mg PO twice daily
Both can be initiated immediately without parenteral bridging. Given his CKD, monitor renal function periodically, but no dose adjustment is needed at eGFR 58.
Common Pitfalls
- Don't reflexively admit all PE patients: Low-risk PE patients can be considered for early discharge with proper outpatient follow-up (Class IIa recommendation) 1
- Don't use IV heparin for stable PE: This is outdated practice; NOACs or LMWH/fondaparinux are preferred 1
- Don't avoid NOACs in moderate CKD: They're safe and effective at eGFR >30 mL/min
- Don't dismiss subsegmental PE in symptomatic patients: The clinical context matters more than the anatomic location 2